| Code | Description | Claims | Beneficiaries | Total Paid |
| J9271 |
Injection, pembrolizumab, 1 mg |
2,263 |
1,801 |
$13.36M |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
69,653 |
52,644 |
$4.46M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
17,319 |
10,400 |
$2.86M |
| 77386 |
|
7,228 |
648 |
$1.98M |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
2,493 |
2,473 |
$1.92M |
| J9299 |
Injection, nivolumab, 1 mg |
370 |
259 |
$1.79M |
| 77412 |
|
12,115 |
1,370 |
$1.49M |
| J9355 |
Injection, trastuzumab, excludes biosimilar, 10 mg |
560 |
329 |
$1.13M |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
18,672 |
18,601 |
$912K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
4,881 |
4,824 |
$881K |
| J2505 |
Injection, pegfilgrastim, 6 mg |
374 |
296 |
$826K |
| 19083 |
|
1,013 |
985 |
$774K |
| 77334 |
|
2,140 |
1,705 |
$663K |
| J9035 |
Injection, bevacizumab, 10 mg |
290 |
161 |
$645K |
| Q5111 |
Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg |
313 |
239 |
$608K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
12,299 |
7,162 |
$491K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
6,266 |
6,192 |
$394K |
| 77336 |
|
5,490 |
2,433 |
$359K |
| 77300 |
|
1,615 |
1,514 |
$314K |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
532 |
419 |
$270K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
1,376 |
1,353 |
$269K |
| 77295 |
|
429 |
381 |
$247K |
| J2506 |
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg |
345 |
269 |
$236K |
| 36512 |
|
400 |
299 |
$235K |
| 96417 |
|
5,852 |
3,975 |
$227K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
2,600 |
1,735 |
$222K |
| 70491 |
|
1,535 |
1,517 |
$212K |
| Q5117 |
Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg |
129 |
89 |
$198K |
| 76642 |
|
7,101 |
6,054 |
$196K |
| 77066 |
Tomosynthesis, mammo |
3,266 |
3,210 |
$191K |
| J9070 |
Cyclophosphamide, 100 mg |
906 |
463 |
$189K |
| 36430 |
|
1,002 |
570 |
$188K |
| 77065 |
Tomosynthesis, mammo |
3,890 |
3,586 |
$173K |
| J0185 |
Injection, aprepitant, 1 mg |
1,253 |
903 |
$155K |
| 31575 |
|
1,886 |
1,827 |
$148K |
| 96415 |
|
2,853 |
2,036 |
$140K |
| 80053 |
Comprehensive metabolic panel |
35,178 |
23,708 |
$140K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,549 |
1,240 |
$136K |
| G0379 |
Direct admission of patient for hospital observation care |
120 |
112 |
$131K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
3,821 |
1,952 |
$127K |
| 96416 |
|
841 |
508 |
$124K |
| 96367 |
|
3,425 |
2,523 |
$122K |
| 78306 |
|
647 |
646 |
$122K |
| 36556 |
|
259 |
188 |
$121K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
8,584 |
8,583 |
$119K |
| J1950 |
Injection, leuprolide acetate (for depot suspension), per 3.75 mg |
123 |
118 |
$117K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
38,105 |
24,946 |
$112K |
| 77290 |
|
550 |
497 |
$89K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
884 |
524 |
$88K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
4,507 |
3,149 |
$78K |
| 36561 |
|
57 |
54 |
$73K |
| 77338 |
|
392 |
366 |
$68K |
| 96411 |
|
1,700 |
1,188 |
$65K |
| 72197 |
|
216 |
216 |
$58K |
| 77301 |
|
85 |
81 |
$56K |
| 88307 |
|
396 |
388 |
$55K |
| 77385 |
|
237 |
12 |
$55K |
| J0897 |
Injection, denosumab, 1 mg |
41 |
38 |
$53K |
| J9217 |
Leuprolide acetate (for depot suspension), 7.5 mg |
148 |
145 |
$49K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
3,311 |
3,208 |
$48K |
| J9306 |
Injection, pertuzumab, 1 mg |
22 |
12 |
$48K |
| 88341 |
|
759 |
741 |
$47K |
| 84443 |
Thyroid stimulating hormone (TSH) |
6,588 |
5,762 |
$45K |
| Q5107 |
Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg |
51 |
24 |
$43K |
| Q3014 |
Telehealth originating site facility fee |
2,422 |
2,303 |
$39K |
| 71250 |
|
641 |
637 |
$36K |
| 96402 |
|
2,062 |
1,966 |
$35K |
| 83735 |
|
11,346 |
6,605 |
$30K |
| 78816 |
|
37 |
37 |
$29K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
516 |
492 |
$26K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
1,132 |
773 |
$24K |
| 86300 |
|
3,004 |
1,329 |
$24K |
| 82784 |
|
3,110 |
2,503 |
$22K |
| 71046 |
Radiologic examination, chest; 2 views |
553 |
539 |
$20K |
| 88342 |
|
815 |
800 |
$20K |
| 77280 |
|
282 |
250 |
$19K |
| 83615 |
|
8,396 |
6,044 |
$19K |
| 86900 |
|
5,177 |
3,620 |
$18K |
| 82378 |
|
2,199 |
1,918 |
$16K |
| 84153 |
|
2,276 |
2,112 |
$16K |
| 86850 |
|
4,850 |
3,368 |
$16K |
| 83521 |
|
1,129 |
1,024 |
$15K |
| 86334 |
|
1,672 |
1,532 |
$14K |
| J1453 |
Injection, fosaprepitant, 1 mg |
294 |
217 |
$14K |
| J9045 |
Injection, carboplatin, 50 mg |
2,209 |
1,464 |
$14K |
| 86304 |
|
1,345 |
1,153 |
$12K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
3,188 |
2,170 |
$10K |
| 76536 |
|
256 |
253 |
$10K |
| J9171 |
Injection, docetaxel, 1 mg |
271 |
135 |
$9K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
281 |
268 |
$9K |
| 84165 |
|
1,985 |
1,810 |
$9K |
| 38505 |
|
12 |
12 |
$8K |
| C8908 |
Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral |
41 |
41 |
$8K |
| 84439 |
|
2,005 |
1,875 |
$8K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
10,555 |
6,809 |
$7K |
| J9267 |
Injection, paclitaxel, 1 mg |
2,636 |
1,167 |
$7K |
| 76641 |
|
276 |
199 |
$7K |
| 96409 |
|
73 |
50 |
$7K |
| 87496 |
|
582 |
249 |
$6K |
| 82728 |
|
1,014 |
851 |
$6K |
| 82565 |
|
3,022 |
2,963 |
$6K |
| 84100 |
|
2,722 |
1,778 |
$6K |
| 84703 |
|
1,747 |
1,466 |
$5K |
| 86901 |
|
5,175 |
3,619 |
$5K |
| C9463 |
Injection, aprepitant, 1 mg |
45 |
27 |
$5K |
| 84403 |
|
474 |
441 |
$5K |
| 86301 |
|
570 |
496 |
$5K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
350 |
340 |
$5K |
| 74183 |
|
39 |
39 |
$5K |
| J3489 |
Injection, zoledronic acid, 1 mg |
395 |
369 |
$5K |
| 85610 |
|
2,789 |
2,449 |
$4K |
| 77080 |
|
77 |
77 |
$4K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,137 |
1,035 |
$3K |
| G0378 |
Hospital observation service, per hour |
257 |
225 |
$3K |
| 94726 |
|
129 |
128 |
$3K |
| 82607 |
|
390 |
376 |
$3K |
| 83540 |
|
462 |
451 |
$3K |
| 85730 |
|
1,358 |
1,163 |
$3K |
| 96401 |
|
172 |
74 |
$3K |
| 78472 |
|
16 |
15 |
$3K |
| J1750 |
Injection, iron dextran, 50 mg |
21 |
12 |
$3K |
| 84702 |
|
334 |
275 |
$2K |
| 84550 |
|
1,031 |
635 |
$2K |
| 36415 |
Collection of venous blood by venipuncture |
14,781 |
11,957 |
$2K |
| 85027 |
|
932 |
737 |
$2K |
| 86923 |
|
212 |
156 |
$2K |
| 86769 |
|
57 |
56 |
$1K |
| 94060 |
|
14 |
14 |
$1K |
| 85046 |
|
508 |
381 |
$1K |
| 81001 |
|
1,021 |
926 |
$1K |
| G0123 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision |
108 |
108 |
$1K |
| J9000 |
Injection, doxorubicin hydrochloride, 10 mg |
303 |
177 |
$1K |
| 82746 |
|
147 |
146 |
$1K |
| 90671 |
|
12 |
12 |
$933.94 |
| 87305 |
|
322 |
147 |
$885.07 |
| 36591 |
|
63 |
59 |
$830.30 |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
12 |
12 |
$780.68 |
| 76830 |
Ultrasound, transvaginal |
12 |
12 |
$780.68 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
12 |
12 |
$776.82 |
| 87625 |
|
40 |
39 |
$614.60 |
| 74160 |
|
43 |
40 |
$566.69 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
42 |
41 |
$515.05 |
| 82533 |
|
50 |
40 |
$505.54 |
| 86800 |
|
61 |
61 |
$487.72 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
340 |
278 |
$468.35 |
| 82570 |
|
167 |
138 |
$445.28 |
| 94760 |
|
623 |
488 |
$441.18 |
| 86706 |
|
109 |
108 |
$437.78 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
13 |
13 |
$424.60 |
| 81003 |
|
401 |
387 |
$356.94 |
| J9263 |
Injection, oxaliplatin, 0.5 mg |
529 |
239 |
$344.98 |
| 84432 |
|
26 |
26 |
$225.39 |
| 36592 |
|
41 |
37 |
$194.37 |
| 77062 |
|
1,576 |
1,574 |
$190.40 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
12 |
12 |
$183.73 |
| 84295 |
|
240 |
231 |
$175.99 |
| 84132 |
|
250 |
239 |
$170.04 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
28 |
28 |
$156.03 |
| 87799 |
|
17 |
13 |
$150.04 |
| 86140 |
|
72 |
39 |
$143.43 |
| J2704 |
Injection, propofol, 10 mg |
3,279 |
3,046 |
$128.69 |
| 84481 |
|
12 |
12 |
$100.27 |
| 85014 |
|
274 |
263 |
$99.03 |
| 84156 |
|
59 |
48 |
$97.22 |
| J3490 |
Unclassified drugs |
24,765 |
8,744 |
$93.35 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
21 |
21 |
$76.68 |
| 77061 |
|
899 |
897 |
$74.10 |
| 84166 |
|
12 |
12 |
$72.69 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
7,324 |
4,517 |
$71.71 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
4,915 |
2,718 |
$50.14 |
| 96549 |
|
640 |
394 |
$42.65 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
2,672 |
2,527 |
$28.27 |
| 88142 |
|
79 |
76 |
$24.14 |
| 81025 |
|
17 |
13 |
$22.56 |
| 96368 |
|
1,110 |
784 |
$21.69 |
| J7050 |
Infusion, normal saline solution, 250 cc |
6,724 |
4,179 |
$8.63 |
| 82330 |
|
56 |
51 |
$8.59 |
| J1720 |
Injection, hydrocortisone sodium succinate, up to 100 mg |
557 |
372 |
$8.31 |
| 87070 |
|
13 |
12 |
$4.75 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
6,515 |
3,926 |
$3.80 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
5,154 |
3,634 |
$3.33 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
5,237 |
3,269 |
$2.93 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
496 |
481 |
$0.94 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
687 |
572 |
$0.00 |
| C1752 |
Catheter, hemodialysis/peritoneal, short-term |
231 |
165 |
$0.00 |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
2,510 |
2,494 |
$0.00 |
| A4216 |
Sterile water, saline and/or dextrose, diluent/flush, 10 ml |
307 |
198 |
$0.00 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
3,797 |
2,143 |
$0.00 |
| J9190 |
Injection, fluorouracil, 500 mg |
971 |
471 |
$0.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
7,264 |
7,073 |
$0.00 |
| J1644 |
Injection, heparin sodium, per 1000 units |
1,252 |
759 |
$0.00 |
| J0640 |
Injection, leucovorin calcium, per 50 mg |
581 |
345 |
$0.00 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
1,280 |
677 |
$0.00 |
| S5000 |
Prescription drug, generic |
1,808 |
1,026 |
$0.00 |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
541 |
450 |
$0.00 |
| 76937 |
|
910 |
785 |
$0.00 |
| J9201 |
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg |
24 |
12 |
$0.00 |
| J1756 |
Injection, iron sucrose, 1 mg |
319 |
169 |
$0.00 |
| 76942 |
|
27 |
26 |
$0.00 |
| 94729 |
|
131 |
130 |
$0.00 |
| 82542 |
|
105 |
66 |
$0.00 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
12 |
12 |
$0.00 |
| 90713 |
|
12 |
12 |
$0.00 |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
27 |
25 |
$0.00 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
40 |
36 |
$0.00 |
| J0688 |
Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg |
17 |
13 |
$0.00 |
| J2004 |
Injection, lidocaine hcl with epinephrine, 1 mg |
37 |
37 |
$0.00 |
| A4648 |
Tissue marker, implantable, any type, each |
1,418 |
1,391 |
$0.00 |
| C1769 |
Guide wire |
788 |
681 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
2,923 |
2,674 |
$0.00 |
| 77417 |
|
534 |
326 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
1,243 |
861 |
$0.00 |
| J3480 |
Injection, potassium chloride, per 2 meq |
424 |
267 |
$0.00 |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
2,977 |
1,941 |
$0.00 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
1,257 |
668 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
712 |
511 |
$0.00 |
| A9503 |
Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries |
503 |
502 |
$0.00 |
| J2060 |
Injection, lorazepam, 2 mg |
204 |
135 |
$0.00 |
| A9585 |
Injection, gadobutrol, 0.1 ml |
1,295 |
1,258 |
$0.00 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
203 |
85 |
$0.00 |
| 77001 |
|
354 |
290 |
$0.00 |
| C1892 |
Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, peel-away |
108 |
97 |
$0.00 |
| 83883 |
|
89 |
80 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
85 |
74 |
$0.00 |
| J9074 |
Injection, cyclophosphamide (sandoz), 5 mg |
18 |
12 |
$0.00 |
| 36410 |
|
14 |
14 |
$0.00 |
| J0610 |
Injection, calcium gluconate (fresenius kabi), per 10 ml |
362 |
232 |
$0.00 |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
27 |
26 |
$0.00 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
13 |
12 |
$0.00 |
| 96376 |
|
83 |
57 |
$0.00 |
| A9579 |
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml |
50 |
47 |
$0.00 |
| J2371 |
Injection, phenylephrine hydrochloride, 20 micrograms |
25 |
24 |
$0.00 |
| J9202 |
Goserelin acetate implant, per 3.6 mg |
12 |
12 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
16 |
12 |
$0.00 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
22 |
12 |
$0.00 |
| A9560 |
Technetium tc-99m labeled red blood cells, diagnostic, per study dose, up to 30 millicuries |
13 |
12 |
$0.00 |